Follow us on Twitter
This page is updated frequently with new Antagonist-related patent applications. Subscribe to the Antagonist RSS feed to automatically get the update: related Antagonist RSS feeds. RSS updates for this page: Antagonist RSS
|| List of recent Antagonist-related patents
|Pyrazole derivatives as modulators of hepatocyte growth factor (scatter factor) activity|
And pharmaceutically acceptable derivatives thereof, wherein r1, r2 and b are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which hgf/sf or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role.. .
|Tamper resistant dosage form comprising an adsorbent and an adverse agent|
Pharmaceutical compositions and dosage forms comprising an adsorbent, and an adverse agent, such as an opioid antagonist. In one embodiment, at least a portion of the adverse agent is on the surface or within the micropore structure of an adsorbent material.
|Polycyclic compounds as lysophosphatidic acid receptor antagonists|
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating lpa-dependent or lpa-mediated conditions or diseases..
|Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity|
The present invention provides compositions and formulations of compounds having formula (i) and pharmaceutically acceptable derivatives thereof, wherein p, r1, r2 and b are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of injuries, conditions or diseases in which hgf/sf or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role. In addition, methods are provided for treating such diseases or diseases starting at a time after the onset of the injury, condition or disease..
|Fsh receptor antagonists|
The invention relates to fsh receptor antagonist according to general formula i or a pharmaceutically acceptable salt thereof and to a pharmaceutical composition containing the same. The compounds can be used for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, and for the treatment of uterine fibroids and other menstrual-related disorders..
|Mineralocorticoid receptor antagonists|
The present invention is directed to compounds of the formula (i) as well as pharmaceutically acceptable salts thereof that are aldosterone receptor antagonists which might be useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the formula (i), to their possible use for the treatment of the above-mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the formula (i)..
|Cancer treatment using bmp inhibitor|
Methods for regulating cancer cell growth and survival, inhibiting cancer cell growth, promoting cancer cell death, and/or treating a cancer make use of antagonists of a type i bmp receptor. In some embodiments the cancer is a lung cancer and the cancer cell is a lung cancer cell..
|Polypeptides involved in immune response|
Novel polypeptides which comprise a receptor-ligand pair involved in t-cell activation are disclosed. Nucleic acid molecules encoding said polypeptides, and vectors and host cells for expressing same are also disclosed.
|Process for the preparation of an endothelin receptor antagonist|
The present invention relates to a novel process for the preparation of a compound of formula (i) wherein r is a methyl or methoxy group; to certain novel intermediates prepared in such a process and their use.. .
|Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations|
Inhalation solutions for administration of muscarinic antagonists for the treatment of breathing disorders, such as copd, are provided.. .
|Methods of treating autoimmune diseases with dll4 antagonists|
The present invention provides methods of treating a disease or disorder, in which increasing the number of regulatory t cell (treg) is beneficial, by administering to a subject suffering from such a disease or disorder a therapeutically effective amount of dll4 antagonists that block dll4-notch signal pathways, thereby increasing the number of treg. Diseases or disorders treatable by the methods of the invention include autoimmune diseases or disorders, such as multiple sclerosis (ms), diabetes, and the like.
|Combination therapy for neoplasia treatment|
The present invention relates to an insulin-like growth factor (igf) receptor antagonist for use in the treatment of prostate neoplasia, including benign prostatic hyperplasia (bph), prostate cancer, and particularly crpc, wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide..
|Oral composition comprising a tnf antagonist and use thereof|
This application further describes a method of treating, preventing or reducing the severity of obesity, the method comprising, administering to the subject a therapeutically effective amount of a tnf antagonist molecule.. .
|Kv1.3 antagonists and methods of use|
The present invention relates to kv1.3 antagonists, and polynucleotides encoding them, and methods of making and using the foregoing.. .
|Methods and compositions for modulation of blood-neural barrier|
Methods and compositions for modulating blood-neural barrier (bnb) for the treatment of cns conditions such as edema, and for increased drug delivery efficacy across the bnb. The present invention further relates to improved tpa treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the pdgf signaling pathway.
|Method of treating rheumatoid arthritis with an anti-il-6r antibody|
The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hil-6r). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (nsaid), a glucocorticoid, a disease-modifying anti-rheumatic drug (dmard), or a tnf-alpha antagonist, t-cell blocker, anti-cd20 antibody, an il-1, jak or il-17 antagonist, or any combination thereof..
|Toll like receptor 3 antagonists, methods and uses|
Toll like receptor 3 (tlr3) antagonists, polynucleotides encoding tlr3 antagonists or fragments, and methods of making and using the foregoing are disclosed.. .
|Microrna modulators and method for identifying and using the same|
The present invention is a method for identifying agents which modulate microrna activity. The invention involves contacting a cell harboring a microrna and a microrna binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent and determining whether the test agent increases or decreases the expression of the reporter protein thereby identifying a microrna modulator.
|Il-1 receptor antagonist-coated electrode and uses thereof|
The present invention provides an electrode designed for implantation into the central nervous system (cns) of a mammal, wherein said electrode is substantially coated with interleukin-1 receptor antagonist (il-1ra) or a coating composition comprising it, and the il-1ra actively inhibits scarring on or around the surface of the electrode when implanted into the cns. The electrode of the invention may be used for brain recording and/or stimulation, and can thus be used for treatment of a brain dysfunction, a brain disease or disorder, or a brain injury, as well as for brain computer interface, brain machine interface, or electrotherapy..
|7-azoniabicyclo[2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof|
Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetylcholine receptor-mediated diseases, such as pulmonary diseases, are provided. .
|5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanomethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists|
Useful in the treatment of diseases and conditions for which antagonism of nk1 receptor is beneficial.. .
|Methods of treating patients suffering from movement disorders|
The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine a2a receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of l-dopa in patients receiving l-dopa therapy in the treatment of parkinson's disease.
|Malignant and non-malignant disease treatment with ras antagonists|
The present disclosure describes new inhibitors or antagonists of ras useful for the treatment of conditions resulting from ras-induced or mediated cellular processes, including cellular proliferation, differentiation, apoptosis, senescence, and survival. These cellular processes may be associated with a non-malignant or malignant disease, disorder, or pathological condition.
|Gene detection assay for improving the likelihood of an effective response to an egfr antagonist cancer therapy|
The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing egfr, as determined by a gene amplification assay, with an egfr antagonist. Such method comprises administering a cancer-treating dose of the egfr antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbb1 gene has been found to be amplified e.g., by fluorescent in situ hybridization.
|Anti-cd40 antibody mutants|
A mutant of a potentially therapeutic anti-cd40 antibody is provided which mutant has reduced adcc and cdc activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-cd40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the adcc and/or cdc activities therein, and a mutant of an antagonistic anti-cd40 antibody, comprising at least one mutation or substitution in the constant region to reduce the adcc and/or cdc activities therein, both mutants having at least a hinge region derived from a human igg2..
|Therapeutic antibodies binding il 12rbeta1|
The present invention relates to antibodies that specifically bind to il12rβ1, the non-signal transducing chain of the heterodimeric il12 receptor (together with il12rβ2 chain) as well as il23 receptor (together with il23rα chain). The invention more specifically relates to specific antibodies that are il12 and il23 receptor antagonists capable of inhibiting il12/il18 induced ifny production of t cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting ifny production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders..
|Antagonists of il17c for the treatment of inflammatory disorders|
The present invention provides antagonists of il17c for use in the treatment of an inflammatory disorder.. .
|Piperidinyl alkyne orexin receptor antagonists|
The present invention is directed to piperidinyl alkyne compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the piperidinyl alkyne compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
|Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists|
The invention is related to methods of preventing and treating hepatic fibrosis using a2b adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method..
|Drug for the treatment of allergic rhinitis comprising pgd2 antagonist and histamine antagonist|
A medicament for treating allergic rhinitis, characterized in that (a) a compound represented by the formula (i) or a pharmaceutically acceptable salt thereof, is combined with (b) at least one compound selected from the group consisting of cetirizine, fexofenadine, and loratadine, or a pharmaceutically acceptable salt thereof. Since the effects of the medicament for treating allergic rhinitis of the present invention surpass the sum of the effects of single dose of each of the agents against the allergic rhinitis, the medicament is useful as a medicament for treating allergic rhinitis having potent effects..
|Polynucleotides encoding signal peptide-containing molecules|
The invention provides human signal peptide-containing proteins (hspp) and polynucleotides which identify and encode hspp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
|Combination therapy for the treatment of ocular neovascular disorders|
The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a pdgf antagonist and a vegf antagonist to the patient. The invention also features a pharmaceutical composition containing a pdgf antagonist and a vegf antagonist for the treatment or prevention of a neovascular disorder..
|Methods and compositions for delivering interleukin-1 receptor antagonist|
Methods and compositions generating and using an interleukin-1 receptor antagonist (il-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating adipose tissue and/or adipocytes with polyacrylamide beads to produce interleukin-1 receptor antagonist.
Wherein r1, r2, r3, r4, r5, r6, r7, w, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl derivatives are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma..
|Fibroblasts cellular model for assessing efficacy of cancer treatments by shh/ptch pathway antagonists|
A cellular model is described that targets dysregulation or inappropriate activation of the sonic hedgehog/patched (shh/ptch) pathway. Also described, is a screening method using this cellular model to screen for pharmacological compounds that can treat or prevent skin cancer, in particular, basal cell carcinoma, (bcc) lesions..
|Food products, preparation, and therapeutic methods|
A method is provided for the supplementation of milk, dairy products, meat products, and other food substances generally considered to be a major part of the western diet, with substances capable of balancing the ratio of methionine and cysteine. Drug therapy with various carbamoyl thioesters or glutamate receptor antagonists can also be used, alone or in combination with dietary supplements and vitamins, to prevent or treat the pathology resulting from a western diet..
|Combination therapy for glaucoma|
Disclosed herein is method of treating glaucoma or ocular hypertension comprising administering a prostaglandin agonist and a second therapeutically active agent to a mammal in need thereof, wherein said second therapeutically active agent is selected from: β-blockers, adrenergic agonists, non-selective adrenergic agonists, α2-selective adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists, direct acting cholinergic agonists, chlolinesterase inhibitors, glutamate antagonists, ca2+ channel blockers, prostamides, prostaglandins, cannabinoids, and combinations thereof. Compositions and medicaments containing a combination of these two active agents are also disclosed..
|New ccr2 receptor antagonists and uses thereof|
The present invention relates to novel antagonists for ccr2 (cc chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and copd.. .
|Compounds and compositions as selective estrogen receptor degraders|
In which n, m, x, y1, r1, r2, r3, r4 and r5 are defined in the summary of the invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity..
|Trpm8 antagonists and their use in treatments|
Where the definitions of the variables are provided herein.. .
Wherein r1 is 2-indanyl, r2 is 1-methylpropyl, r3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, r4 represents methyl and r5 represents hydrogen or methyl or, r4 and r5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.. .
Wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human s1p2 antagonistic activity. The compound may therefore be used as a therapeutic agent for s1p2-mediated diseases such as diseases resulting from vascular constriction, fibrosis and respiratory diseases..
|Compositions and methods for suppressing endometrial proliferation|
The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and/or selective estrogen receptor modulator (serm) therapy.
|Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists|
The present invention relates to compounds of formula (i), combinations and use thereof for disease therapy, or pharmaceutically acceptable salt or solvate thereof, including all tautomers, stereoismers and polymorphs thereof, which are iglur receptor inhibitors, and hence are useful in the treatment of psychiatric diseases or neurological disorders or a disease or disorder associated with abnormal activities of iglur receptors.. .
|Methods for treating neural cell swelling|
A composition comprising a novel ca2+-activated, [atp]i-sensitive nonspecific cation (ncca-atp) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [ca]i.
|Glycoproteins having lipid mobilizing properties and therapeutic uses thereof|
The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering zn-α2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents.. .
|Ligands modified by circular permutation as agonists and antagonists|
The present invention provides fusion polypeptides comprising polypeptide ligands that are modified by circular permutation and fused to at least one polypeptide fusion partner wherein such fusion polypeptides have new, improved or enhanced biological functions or activities. Such improvements include, but are not limited to, increased binding affinity, increased activity, increased agonist activity (super agonist), antagonist activity, increased accessibility, increased flexibility of the active site, increased stability, broader and/or changed substrate specificity, and combinations thereof..
|Controlled platelet activation to monitor therapy of adp antagonists|
A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or gpiib/iiia blockade. A blood sample is obtained from the individual being assessed.
|Il-17 receptor a is required for il-17c biology|
The present invention relates to interleukin-17 ligand and receptor family members and the discovery that il-17 receptor a and il-17 receptor e form a heteromeric receptor complex that is biologically active, and that il-17c activity requires the il-17ra-il-17re heteromeric receptor complex. Antagonists of the il-17ra-il-17re heteromeric receptor complex are disclosed, as well as various methods of use..
|Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury|
Disclosed are transgenic non-human mammals, which useful for the screening of thrombopoietin mimetics, thrombopoietin receptor agonists, or thrombopoietin receptor antagonists active on the human thrombopoietin receptor. The transgenic non-human mammal has a genome that comprises a stably integrated transgene construct comprising a polynucleotide sequence encoding a humanized thrombopoietin receptor wherein said transgenic non-human mammal has a baseline blood platelet count corresponding to a physiological blood platelet count of a matched non-transgenic non-human mammal.
|Inhibition of tumor metastasis|
The invention provides nrp2 antagonists, such as anti-nrp2 antibodies, and their use in the prevention and treatment of tumor metastasis.. .
|Modulation of pilr to treat immune disorders|
The present invention provides methods of using pilrα agonists, or pilrβ antagonists, to treat immune disorders, such as autoimmune and inflammatory disorders, including cns, joint and gut inflammation.. .
|Therapies for chronic renal failure using one or more integrin antagonists|
The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain integrin antagonists..
|Thienopyrimidinone derivatives as mglur1 antagonists|
Disclosed are thienopyrimidinone derivatives as antagonists that act on metabotropic glutamate receptor subtype 1. The thienopyrimidinone derivatives show pharmacological activity against metabotropic glutamate receptor-related diseases, including pain, such as neuropathic pain and migraine, psychiatric diseases, such as anxiety disorder and schizophrenia, urinary incontinence, and neurodegenerative diseases, such as parkinson's disease and alzheimer's disease.
|Novel compounds modulating the hedgehog protein signaling pathway, marked forms thereof, and applications|
The invention relates to compounds of formula (i), and the use thereof as a drug, particularly for the treatment of tumors associated with hyperactivation of the hedgehog protein signaling pathway, treatment of neurodegenerative diseases, treatment of diseases related to cerebral development (holoprosencephaly), for stem cell monitoring treatment of cerebrovascular accidents and cardiovascular accidents, treatment of diseases involving oligodendrocytes and diseases involving neurolemmocytes, for application thereof in vitro for modulating human or animal stem cell renewal, and for the treatment of diabetes. The invention also relates to pharmaceutical compositions having a compound of formula (i).
|Combinations of alpha 7 nicotinic acetylcholine receptor activators and mglur5 antagonists for use in dopamine induced dyskinesia in parkinson's disease|
The present invention relates to novel combinations suitable for the treatment of dyskinesia associated with dopamine agonist therapy in parkinson's disease, which comprise, as active ingredients, at least one low molecular weight nicotinic acetylcholine receptor alpha 7 activator and at least one low molecular weight metabotropic glutamate receptor 5 antagonist; to their preparation; to their use as medicaments and to medicaments comprising them.. .
|N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists|
The invention provides novel substituted cyclopropane carboxamide compounds according to formula (i), their manufacture and use for the treatment of proliferative or inflammatory diseases, such as cancer, fibrosis or arthritis.. .
A compound represented by formula (ia) or a pharmaceutically acceptable salt thereof, which acts relying on an orexin (ox) receptor antagonistic activity and is useful for the treatment or prevention of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, alzheimer's disease, parkinson's disease, huntington's chorea, eating disorder, head ache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases and hypertension.. .
|Method of treatment or prophylaxis|
The present invention is directed to methods and agents that are useful in the prevention and amelioration of signs and symptoms associated with neuropathic conditions. More particularly, the present invention discloses the use of angiotensin ii receptor 2 (at2 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of neuropathic pain, including mechanical hyperalgesia, thermal or mechanical allodynia, diabetic pain and entrapment pain, in vertebrate animals and particularly in human subjects.
|Compounds and methods of treating diabetes|
Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α2a.
Combinations suitable for agricultural use can include (i) a nematode-antagonistic biocontrol agent and (ii) one or more agents selected, independently of each other, from any one of (a) to (h): (a) at least one fungicide; (b) at least one insecticide; (c) at least one synthetic nematicide; (d) bacterium of the genus bacillus; (e) harpin; (f) isoflavones; (g) plant growth regulators; and/or (h) plant activators.. .
|G protein coupled receptor agonists and antagonists and methods of activating and inhibiting g protein coupled receptors using the same|
The invention relates generally to g protein coupled receptors and in particular to agonists and antagonists of g protein receptors and methods of using the same.. .
|Antibodies to human signal peptide-containing proteins|
The invention provides a human signal peptide-containing proteins (sigp) and polynucleotides which identify and encode sigp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
|Nogo receptor antagonists|
Disclosed are immunogenic nogo receptor-1 polypeptides, nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are nogo receptor antagonist polynucleotides.
|Pd-1 antagonists and methods for treating infectious disease|
Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid t cell mediated responses, (2) induction of t cell exhaustion, t cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and/or other apcs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired t cell inhibition by binding to and blocking pd-1 to prevent or reduce inhibitory signal transduction, or by binding to ligands of pd-1 such as pd-l1, thereby preventing (in whole or in part) the ligand from binding to pd-1 to deliver an inhibitory signal.
|Humanized anti-cmet antagonists|
The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.. .
|Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof|
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase i (alk1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of bmp9 and/or bmp10, ligands for alk1, may also be used to inhibit angiogenesis in vivo..
|Methods and monitoring of treatment with a dll4 antagonist|
Methods for treating diseases such as cancer comprising administering a dll4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.. .
Popular terms: [SEARCH]
Antagonist topics: Antagonist, Recurrence, Proliferative Disorder, Proliferative, Antibodies, Progesterone, Dicyclomine, Scopolamine, Extracellular, Pharmaceutically Acceptable Salt, Metalloprotein, Nucleic Acids, Polynucleotide, Nucleic Acid, Monoclonal
Follow us on Twitter
This listing is a sample listing of patent applications related to Antagonist for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antagonist with additional patents listed. Browse our RSS directory or Search for other possible listings.